Louis Garguilo

ARTICLES BY LOUIS

  • 6/25/2024

    The U.S. House Rules Committee did not include the BIOSECURE Act in the final list of amendments for the National Defense Authorization Act (NDAA). Chief Editor Louis Garguilo has been outspoken in defending WuXi Apptec’s right to due process. Readers have responded in spades. Here's the latest.

  • 6/24/2024

    “I always say I’ve brought a little New Jersey litigator to Pittsburgh biotech,” says BlueSphere Bio CEO Keir Loiacono. And to the CDMOs he works with. Today, his attorney-informed focus is applied to T cell receptor (TCR) technology. Here's part one of his unique insights to outsourcing.

  • 6/18/2024

    Secretly, somewhere inside you, is the thought: I’d like to leave this job at my established biopharma company. You wonder: How would I start my own, wait for it: contract service organization? Jeffrey Kiplinger, formerly of Pfizer, did just that. And wrote a book about it.  

  • 6/13/2024

    An experienced healthcare investor/consultant, and former biotech CEO, puts on his thinking cap to provide readers some intriguing insights into your development and manufacturing outsourcing, and overall business model for new drugs and therapies.

  • 6/10/2024

    An integral FDA touchstone with your CDMOs is drug master files (DMFs). Ben Stevens, Director CMC Policy and Advocacy at GSK, advises readers on how to avoid the ramifications taking you by unpleasant surprise.

  • 6/7/2024

    Consultants coordinating with investors offer an ecosystem around the molecule being developed at a biotech, and help to reevaluate development decisions in a more dispassionate way.” Dispassion applied specifically to ultimate commercial profitability.

  • 6/3/2024

    Don’t panic if you aren’t familiar with the above acronym, which stands for Quality Management Maturity. Chief Editor Louis Garguilo wasn't – until schooled by Jason Kerr, Regulatory Intelligence Senior Manager, Moderna and Adjunct Professor of Quality Systems, Keck Graduate Institute. QMM, it appears, may very well be in your future.

  • 5/23/2024

    Ben Stevens of GSK documents his career, and highlights a stage in outsourcing we often overlook   key interactions between med-chem scientists and research biologists, and contract development and manufacturing providers (CDMOs).

  • 5/20/2024

    “As you read these accusations, it’s like an attempted death by a thousand implications,” says Rick Connell, former Pfizer supply-chain executive and current WuXi AppTec President, U.S. and Europe. In this part two, he provides a line-by-line analysis of the BIOSECURE Act targeting his company.

  • 5/14/2024

    Chief Editor Louis Garguilo opens the 2024 Leadership Awards with an acknowledgement of the vital role CDMOs play, and also an intriquing insight into this year’s data to determine the award winners.

louis-g-photo-edited

Louis Garguilo



Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.

Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.